| scholarly article | Q13442814 |
| P50 | author | António R Pombinho | Q56480104 |
| Petr Bartůněk | Q59689457 | ||
| Magdalena Klánová | Q39185457 | ||
| Pavel Klener | Q39185479 | ||
| Jan Molinsky | Q43704022 | ||
| P2093 | author name string | Ladislav Andera | |
| Michal Koc | |||
| Jarmila Spegarova | |||
| Lenka Beranova | |||
| P2860 | cites work | Bortezomib primes glioblastoma, including glioblastoma stem cells, for TRAIL by increasing tBid stability and mitochondrial apoptosis | Q24300558 |
| DJ-1 inhibits TRAIL-induced apoptosis by blocking pro-caspase-8 recruitment to FADD | Q24316876 | ||
| Identification of a novel pro-apoptotic role of NF-κB in the regulation of TRAIL- and CD95-mediated apoptosis of glioblastoma cells | Q24319961 | ||
| Identification of an antiapoptotic protein complex at death receptors | Q24321594 | ||
| Tumor necrosis factor-related apoptosis-inducing ligand-induced death-inducing signaling complex and its modulation by c-FLIP and PED/PEA-15 in glioma cells | Q28215810 | ||
| The long form of FLIP is an activator of caspase-8 at the Fas death-inducing signaling complex | Q28221276 | ||
| Superior antitumoral activity of dimerized targeted single-chain TRAIL fusion proteins under retention of tumor selectivity | Q28729760 | ||
| Novel SMAC-mimetics synergistically stimulate melanoma cell death in combination with TRAIL and Bortezomib | Q33906039 | ||
| Suppression of apoptosis inhibitor c-FLIP selectively eliminates breast cancer stem cell activity in response to the anti-cancer agent, TRAIL. | Q34018500 | ||
| New insights into apoptosis signaling by Apo2L/TRAIL. | Q34022690 | ||
| Model-based dissection of CD95 signaling dynamics reveals both a pro- and antiapoptotic role of c-FLIPL. | Q34069986 | ||
| Homoharringtonine: history, current research, and future direction | Q34105271 | ||
| Nimbolide sensitizes human colon cancer cells to TRAIL through reactive oxygen species- and ERK-dependent up-regulation of death receptors, p53, and Bax. | Q34488880 | ||
| Molecular modes of action of cephalotaxine and homoharringtonine from the coniferous tree Cephalotaxus hainanensis in human tumor cell lines | Q44343089 | ||
| Translation inhibitors sensitize prostate cancer cells to apoptosis induced by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) by activating c-Jun N-terminal kinase | Q44381498 | ||
| TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-kappaB. | Q44482351 | ||
| Homoharringtonine inhibits the AKT pathway and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells | Q46298902 | ||
| Leukemia-initiating cells of patient-derived acute lymphoblastic leukemia xenografts are sensitive toward TRAIL. | Q48032022 | ||
| MADD/DENN splice variant of the IG20 gene is a negative regulator of caspase-8 activation. Knockdown enhances TRAIL-induced apoptosis of cancer cells | Q50337127 | ||
| Omacetaxine mepesuccinate for the treatment of leukemia. | Q52892987 | ||
| Omacetaxine mepesuccinate prevents cytokine-dependent resistance to nilotinib in vitro: potential role of the common β-subunit c of cytokine receptors. | Q54326636 | ||
| The cyclin-dependent kinase inhibitor R-roscovitine down-regulates Mcl-1 to override pro-inflammatory signalling and drive neutrophil apoptosis. | Q54694804 | ||
| Homoharringtonine reduced Mcl-1 expression and induced apoptosis in chronic lymphocytic leukemia | Q34568840 | ||
| The role of TRADD in TRAIL-induced apoptosis and signaling | Q34682495 | ||
| Conscripts of the infinite armada: systemic cancer therapy using nanomaterials. | Q35545342 | ||
| Quercetin-mediated Mcl-1 and survivin downregulation restores TRAIL-induced apoptosis in non-Hodgkin's lymphoma B cells | Q35643014 | ||
| Wogonin and related natural flavones overcome tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) protein resistance of tumors by down-regulation of c-FLIP protein and up-regulation of TRAIL receptor 2 expression | Q35643815 | ||
| Synergistic TRAIL sensitizers from Barleria alluaudii and Diospyros maritima | Q35850815 | ||
| On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics | Q35853714 | ||
| Mechanisms of resistance to TRAIL-induced apoptosis in cancer | Q35954258 | ||
| Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors | Q36852093 | ||
| Synthesis of antiproliferative Cephalotaxus esters and their evaluation against several human hematopoietic and solid tumor cell lines: uncovering differential susceptibilities to multidrug resistance | Q37074659 | ||
| Mcl-1: a gateway to TRAIL sensitization. | Q37125357 | ||
| Current constructs and targets in clinical development for antibody-based cancer therapy | Q37387364 | ||
| Cellular FLICE-inhibitory protein (c-FLIP) signalling: a key regulator of receptor-mediated apoptosis in physiologic context and in cancer | Q37637257 | ||
| Mitochondrially targeted anti-cancer agents | Q37769939 | ||
| TRAIL receptor signaling and therapeutics. | Q37785559 | ||
| Combined modality therapy with TRAIL or agonistic death receptor antibodies. | Q37832083 | ||
| Developing histone deacetylase inhibitors as anti-cancer therapeutics | Q37856325 | ||
| Targeting the extrinsic apoptosis signaling pathway for cancer therapy | Q37882480 | ||
| A survey of marine natural compounds and their derivatives with anti-cancer activity reported in 2010. | Q37945009 | ||
| State of art and recent developments of anti-cancer strategies based on TRAIL. | Q37960569 | ||
| The therapeutic potential of TRAIL receptor signalling in cancer cells. | Q37962655 | ||
| Histone deacetylase (HDAC) inhibitors and regulation of TRAIL-induced apoptosis | Q37988252 | ||
| Thapsigargin sensitizes human melanoma cells to TRAIL-induced apoptosis by up-regulation of TRAIL-R2 through the unfolded protein response. | Q38299743 | ||
| Targeting FLIP and Mcl-1 using a combination of aspirin and sorafenib sensitizes colon cancer cells to TRAIL. | Q39248620 | ||
| Distinct TRAIL resistance mechanisms can be overcome by proteasome inhibition but not generally by synergizing agents. | Q39583729 | ||
| FLIP(L) induces caspase 8 activity in the absence of interdomain caspase 8 cleavage and alters substrate specificity | Q39694237 | ||
| Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death. | Q40110911 | ||
| TRAIL/bortezomib cotreatment is potentially hepatotoxic but induces cancer-specific apoptosis within a therapeutic window. | Q40165924 | ||
| Selective knockdown of the long variant of cellular FLICE inhibitory protein augments death receptor-mediated caspase-8 activation and apoptosis. | Q40448034 | ||
| Tipping the Noxa/Mcl-1 balance overcomes ABT-737 resistance in chronic lymphocytic leukemia | Q42802658 | ||
| Identification of c-FLIP(L) and c-FLIP(S) as critical regulators of death receptor-induced apoptosis in pancreatic cancer cells | Q42874678 | ||
| P433 | issue | 6 | |
| P921 | main subject | multiple drug resistance | Q643839 |
| (-)-homoharringtonine | Q7089373 | ||
| colorectal carcinoma | Q25493920 | ||
| P304 | page(s) | 739-750 | |
| P577 | publication date | 2013-06-01 | |
| P1433 | published in | Apoptosis | Q15749546 |
| P1476 | title | The plant alkaloid and anti-leukemia drug homoharringtonine sensitizes resistant human colorectal carcinoma cells to TRAIL-induced apoptosis via multiple mechanisms | |
| P478 | volume | 18 |
| Q35882493 | Bay 61-3606 Sensitizes TRAIL-Induced Apoptosis by Downregulating Mcl-1 in Breast Cancer Cells |
| Q46316687 | Cephalotaxus Alkaloids |
| Q36260575 | Citrus limon-derived nanovesicles inhibit cancer cell proliferation and suppress CML xenograft growth by inducing TRAIL-mediated cell death. |
| Q35600313 | Efficient drug delivery and induction of apoptosis in colorectal tumors using a death receptor 5-targeted nanomedicine |
| Q98499791 | Homoharringtonine suppresses tumor proliferation and migration by regulating EphB4-mediated β-catenin loss in hepatocellular carcinoma |
| Q38880884 | Homoharringtonine, a clinically approved anti-leukemia drug, sensitizes tumor cells for TRAIL-induced necroptosis |
| Q64230629 | Human Embryonic Stem Cells Acquire Responsiveness to TRAIL upon Exposure to Cisplatin |
| Q42915261 | Human embryonic and induced pluripotent stem cells express TRAIL receptors and can be sensitized to TRAIL-induced apoptosis. |
| Q58759678 | Liposomal Co-Delivery of Omacetaxine Mepesuccinate and Doxorubicin for Synergistic Potentiation of Antitumor Activity |
| Q38760939 | Nucleostemin dysregulation contributes to ischemic vulnerability of diabetic hearts: Role of ribosomal biogenesis |
| Q38789476 | Omacetaxine mepesuccinate induces apoptosis and cell cycle arrest, promotes cell differentiation, and reduces telomerase activity in diffuse large B‑cell lymphoma cells |
Search more.